Novo Nordisk's Ozempic, Wegovy sales jump 40% in India after steep price cuts
Novo Nordisk moved 32,000 units of Ozempic and Wegovy in India in April 2026, a 40% surge after slashing prices 36-48%. Starting doses now retail at Rs 5,660 as the Danish drugmaker defends share against newly launched generic semaglutide rivals in the booming obesity drug market.
Novo Nordisk's Ozempic and Wegovy sales jumped 40% in India in April 2026 to 32,000 units after 36-48% price cuts brought starting doses to Rs 5,660, defending share against newly launched generic semaglutide.
Why this matters
Novo Nordisk is repricing aggressively in India to protect its semaglutide franchise as patent expiry opens the door to generic competitors entering the fast-growing obesity drug market.
Retail-brand signals steady at 1,730 over the past 90 days.
Also reported by
- Moneycontrol — Same time
- Moneycontrol · News Web — Same time